Dr. Lal Path Labs Limited has executed a Fifth Supplementary Trust Deed to amend its Employee Welfare Trust, incorporating the newly approved Restricted Stock Unit Plan 2025. The amendment was completed on December 9, 2025, and registered with the Sub-Registrar of Assurances in New Delhi on December 10, 2025.

New RSU Plan Integration

The trust deed amendment follows the shareholders' approval of the Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025) through a special resolution passed on December 7, 2025. The modification ensures compliance with SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

Trust Structure and Trustees

The Employee Welfare Trust operates under three designated trustees who will oversee the implementation of the new RSU plan:

• Mr. Munender Soperna: Group Chief Information & Digital Officer, aged 51 years
• Dr. Reena Nakra: Principal Director, Lab Management Technical Excellence, aged 53 years
• Mr. Manoj Kumar Garg: Group Chief Human Resources Officer, aged 57 years

Expanded Employee Benefit Plans

The amended trust deed now encompasses a comprehensive range of employee benefit schemes under the expanded definition of "Plan":

• Dr. Lal PathLabs Employee Stock Option Plan 2010 (ESOP 2010)
• Dr. Lal PathLabs Employee Share Purchase Scheme 2015 (ESPS 2015)
• Dr. Lal PathLabs Employee Restricted Stock Unit 2016 (RSU 2016)
• Dr. Lal PathLabs Employee Stock Option Plan 2022 (ESOP 2022)
• Dr. Lal PathLabs Employee Restricted Stock Unit Plan 2025 (RSU 2025)
• Any future employee benefit plans with provisions for modifications

Trust Evolution Timeline

The Employee Welfare Trust has undergone multiple amendments since its establishment:

Regulatory Compliance

The Fifth Supplementary Trust Deed maintains continuity with all previous amendments while specifically addressing the requirements of the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The document establishes that in case of conflicts between different versions, the provisions of the Fifth Supplementary Trust Deed will prevail for matters specifically addressed therein.

The trust deed amendment represents Dr. Lal PathLabs' continued commitment to employee welfare through structured equity participation programs, ensuring regulatory compliance while expanding benefit options for eligible employees.

Dr. Lal Path Labs , a leading diagnostic chain in India, has taken a significant step forward in enhancing the country's healthcare capabilities. The company has launched India's first complete complement testing laboratory, introducing a range of tests that are being offered for the first time in the nation.

Advancing Autoimmune Disease Diagnostics

This groundbreaking initiative aims to revolutionize the diagnosis and treatment of autoimmune diseases through specialized testing services. The complement system, a crucial part of the immune system, plays a vital role in the body's defense against pathogens. However, it can also contribute to the development of autoimmune disorders when not functioning properly.

Key Highlights of the New Laboratory

• First of its Kind: Dr. Lal PathLabs' new facility is the first complete complement testing laboratory in India.
• Novel Tests: The laboratory introduces tests that were previously unavailable in the country.
• Focus on Autoimmune Diseases: The initiative is specifically designed to improve diagnostic capabilities for autoimmune conditions.
• Enhanced Treatment Potential: By offering more comprehensive testing, the laboratory aims to facilitate better treatment strategies for patients with autoimmune diseases.

Implications for Healthcare in India

The introduction of this specialized laboratory by Dr. Lal PathLabs represents a significant advancement in India's diagnostic capabilities. It has the potential to:

1. Improve early detection of autoimmune diseases
2. Enhance the accuracy of diagnoses
3. Enable more targeted and effective treatment plans
4. Contribute to research and understanding of autoimmune disorders in the Indian population

This development underscores Dr. Lal PathLabs' commitment to innovation and improving healthcare outcomes in India. As autoimmune diseases continue to pose significant challenges worldwide, such advancements in diagnostic capabilities are crucial for better patient care and management.

The launch of this specialized laboratory not only positions Dr. Lal PathLabs at the forefront of diagnostic innovation in India but also has the potential to significantly impact the lives of patients suffering from autoimmune diseases across the country.